HC Wainwright reissued their buy rating on shares of Mersana Therapeutics (NASDAQ:MRSN) in a report published on Thursday morning, AnalystRatings.com reports. They currently have a $7.00 price objective on the stock.
A number of other analysts also recently commented on the stock. Zacks Investment Research upgraded shares of Mersana Therapeutics from a sell rating to a hold rating in a report on Wednesday, October 23rd. ValuEngine upgraded shares of Mersana Therapeutics from a hold rating to a buy rating in a report on Thursday, August 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. Mersana Therapeutics currently has a consensus rating of Buy and a consensus target price of $7.83.
Shares of NASDAQ MRSN traded up $0.10 during midday trading on Thursday, hitting $2.08. The company’s stock had a trading volume of 184,700 shares, compared to its average volume of 239,771. Mersana Therapeutics has a 1-year low of $1.32 and a 1-year high of $7.65. The firm has a market cap of $88.45 million, a P/E ratio of -0.75 and a beta of 1.51. The firm’s fifty day moving average price is $1.68 and its 200-day moving average price is $3.30. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.50 and a current ratio of 5.50.
Mersana Therapeutics (NASDAQ:MRSN) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.02. Mersana Therapeutics had a negative net margin of 77.78% and a negative return on equity of 51.13%. The company had revenue of $0.84 million for the quarter, compared to the consensus estimate of $0.50 million. As a group, research analysts predict that Mersana Therapeutics will post -0.62 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in MRSN. Marshall Wace LLP bought a new stake in shares of Mersana Therapeutics in the 1st quarter worth approximately $141,000. Acadian Asset Management LLC bought a new stake in shares of Mersana Therapeutics in the 2nd quarter worth approximately $204,000. Russell Investments Group Ltd. raised its holdings in shares of Mersana Therapeutics by 41.8% in the 2nd quarter. Russell Investments Group Ltd. now owns 13,900 shares of the company’s stock worth $56,000 after purchasing an additional 4,100 shares in the last quarter. Panagora Asset Management Inc. bought a new stake in shares of Mersana Therapeutics in the 2nd quarter worth approximately $397,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Mersana Therapeutics by 144.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 85,045 shares of the company’s stock worth $345,000 after purchasing an additional 50,195 shares in the last quarter. Institutional investors and hedge funds own 83.46% of the company’s stock.
About Mersana Therapeutics
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.
Further Reading: Initial Coin Offerings entail a high degree of risk
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.